Search results for " DIABETES MELLITUS"

showing 10 items of 309 documents

Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and de…

2015

Abstract Objectives Severe hypoglycemia is associated with cognitive decline and dementia in older persons with type 2 diabetes. The role of antidiabetic treatments on severe hypoglycemia is unknown in dementia. The aims were to determine the prevalence of severe hypoglycemic events and investigate associations among severe hypoglycemic and specific antidiabetic treatments (classes of oral agents and types of insulin analogs) in a large sample of nursing home patients with diabetes according to dementia status. Design Cross-sectional observational study. Setting A total of 150 nursing homes across Italy. Participants A total of 2258 patients with type 2 diabetes (dementia = 1138, no dementi…

Blood GlucoseMaleAgingSevere hypoglycemia dementia insulin analogs antidiabetic oral agents agingmedicine.medical_treatmentInsulin analogAdministration OralType 2 diabetesSeverity of Illness IndexInsulin AntagonistsReference ValuesOdds RatioPrevalenceHomes for the AgedInsulinReference ValueCognitive declineNursing (all)2901 Nursing (miscellaneous)General NursingAged 80 and overInsulin AntagonistMedicine (all)Health PolicyAging; Antidiabetic oral agents; Dementia; Insulin analogs; Severe hypoglycemia; Administration Oral; Age Distribution; Aged; Aged 80 and over; Blood Glucose; Confidence Intervals; Cross-Sectional Studies; Dementia; Diabetes Mellitus Type 2; Female; Homes for the Aged; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Antagonists; Italy; Logistic Models; Male; Middle Aged; Nursing Homes; Odds Ratio; Prevalence; Prognosis; Reference Values; Risk Assessment; Severity of Illness Index; Sex Distribution; Sulfonylurea Compounds; Nursing (all)2901 Nursing (miscellaneous); Health PolicyGeneral MedicineMiddle AgedPrognosisSulfonylurea CompoundNursing HomeItalyFemaleHumanmedicine.medical_specialtyLogistic ModelPrognosiHypoglycemiaelderly patientsRisk AssessmentAge DistributionInternal medicineDiabetes mellitusmedicineConfidence IntervalsDementiaHumansHypoglycemic AgentsSex DistributionAgedAntidiabetic oral agentCross-Sectional StudieSevere hypoglycemiaHypoglycemic Agentbusiness.industryInsulinOdds ratiomedicine.diseaseHypoglycemiaNursing HomesEndocrinologyCross-Sectional StudiesLogistic ModelsSulfonylurea CompoundsDiabetes Mellitus Type 2DementiaGeriatrics and GerontologybusinessConfidence IntervalBody mass indexJournal of the American Medical Directors Association
researchProduct

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular …

2012

Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…

Blood GlucoseMaleBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAEndocrinology Diabetes and Metabolismpioglitazone sulfonylurea type 2 diabetes metformin cardiovascular eventsMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - EndocrinologiaBody Mass Indexlaw.inventionRandomized controlled trialRisk FactorslawSurveys and QuestionnairesCardiovascular DiseasepioglitazonepiogllitazoneStrokeDiabetes Therapy PioglitazoneNutrition and DieteticsDiabetesThiazolidinedionecardiovascular events; pioglitazone; Type 2 Diabetes Mellitus; sulphonylureasType 2 diabetesMiddle AgedMetforminSulfonylurea CompoundTreatment OutcomeTolerabilitysulphonylureasCardiovascular DiseasesDrug Therapy CombinationFemaletype 2 diabetesCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyEndpoint Determinationsulfonylureacardiovascualr eventSudden deathFollow-Up Studiecardiovascular eventsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentssulfonylureasinterventio trialtype 2 diabetes; cardiovascular events; pioglitazone; sulfonylureas; randomized controlled trialAgedHypoglycemic AgentQuestionnairebusiness.industryRisk Factormedicine.diseaseSurgeryType 2 Diabetes MellitusSulfonylurea CompoundsDiabetes Mellitus Type 2randomized controlled trialQuality of LifeThiazolidinedionesTherapybusinessmetforminPioglitazoneFollow-Up Studies
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospe…

2019

Abstract Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP‐1RA as second or a more advanced line of therapy. Materials and methods DARWIN‐T2D was a retrospective multi‐centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP‐1RA (exenatide once weekly or liraglutide). Data were c…

Blood GlucoseMaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismBlood PressureType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesClinical endpointMedicineDapagliflozinGLP-1 analogueMiddle AgedTreatment Outcomeglycaemic controlantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational studyCombinationOriginal ArticleDrug Therapy CombinationFemaleType 2medicine.drugAdultmedicine.medical_specialty030209 endocrinology & metabolismGlucagon-Like Peptide-1 Receptor03 medical and health sciencesDrug TherapyGLP-1 analogue; antidiabetic drug; dapagliflozin; glycaemic control; observational studyGLP‐1 analogueInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinantidiabetic drugantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational study; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus Type 2; Diabetic Angiopathies; Drug Therapy Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcomebusiness.industryLiraglutideBody WeightRetrospective cohort studyOriginal ArticlesdapagliflozinLiraglutidemedicine.diseaseBlood pressureDiabetes Mellitus Type 2chemistryPropensity score matchingExenatideobservational studybusinessAntidiabetic drug dapagliflozin GLP-1 analogue glycaemic control observational studyDiabetic Angiopathies
researchProduct

Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.

2021

Background and aims: To evaluate the change in circulating serum irisin and interleukin-6 (IL-6), in patients with type 2 diabetes mellitus (T2DM) after 6 and 12 months of GLP-1 treatment. Methods and results: Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment. After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase in s…

Blood GlucoseMaleIrisinmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRecombinant Fusion ProteinsGlucagon-Like PeptidesMedicine (miscellaneous)IncretinsGlucagon-Like Peptide-1 ReceptorSettore MED/13 - EndocrinologiaProinflammatory cytokineAdipokineInternal medicineMyokinemedicineHumansHypoglycemic AgentsInsulinIn patientDulaglutideGlucagon-like peptide 1 receptorAgedNutrition and DieteticsLiraglutidebusiness.industryInterleukin-6InsulinType 2 Diabetes MellitusLiraglutideMiddle AgedFibronectinsImmunoglobulin Fc FragmentsSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaEndocrinologyCholesterolTreatment OutcomeDiabetes Mellitus Type 2DulaglutideDrug Therapy CombinationFemaleInflammation MediatorsWaist CircumferenceCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Impact of a Mediterranean Dietary Pattern and Its Components on Cardiovascular Risk Factors, Glucose Control, and Body Weight in People with Type 2 D…

2018

This study evaluates the relation of a Mediterranean dietary pattern and its individual components with the cardiovascular risk factors profile, plasma glucose and body mass index (BMI) in people with type 2 diabetes. We studied 2568 participants at 57 diabetes clinics. Diet was assessed with the EPIC (European Prospective Investigation into Cancer and Nutrition) questionnaire, adherence to the Mediterranean diet was evaluated with the relative Mediterranean diet score (rMED). A high compared to a low score was associated with a better quality of diet and a greater adherence to the nutritional recommendations for diabetes. However, even in the group achieving a high score, only a small prop…

Blood GlucoseMaleMediterranean diet; cardiovascular risk; diabetes; glucose control; plasma lipids; relative Mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Healthy; Diet Mediterranean; Feeding BehaviorGlycated Hemoglobin AMediterranean dietRecommended Dietary AllowanceCross-sectional studyHealthy DietSaturated fatBlood PressureType 2 diabetes030204 cardiovascular system & hematologyMediterraneanDiet MediterraneanDiabeteRecommended Dietary AllowancesSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compound0302 clinical medicineRisk FactorsCardiovascular Disease030212 general & internal medicineNutrition and DieteticsdiabetesLipidMiddle AgedLipidsEuropean Prospective Investigation into Cancer and NutritionCardiovascular DiseasesFemaleDiet Healthylcsh:Nutrition. Foods and food supplyNutritive ValueType 2Humancardiovascular riskCardiovascular risk; Diabetes; Glucose control; Mediterranean diet; Plasma lipids; Relative mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Mediterranean; Feeding Behavior; Healthy Diet; Food Science; Nutrition and DieteticsPlasma lipidlcsh:TX341-641Article03 medical and health sciencesEnvironmental healthDiabetes mellitusMediterranean dietplasma lipidsmedicineDiabetes MellitusHumansProtective FactorAgedCross-Sectional StudieGlycated Hemoglobinglucose controlHealthybusiness.industryRisk FactorBiomarkerFeeding Behaviorrelative Mediterranean diet scoreProtective Factorsmedicine.diseaseDietCross-Sectional StudieschemistryDiabetes Mellitus Type 2Patient ComplianceGlycated hemoglobinbusinessBody mass indexBiomarkersFood Science
researchProduct

Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism

2018

Background: Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of cardiovascular (CV) events. The ingestion of high-glycemic index (GI) diets, specially sweetened beverage consumption, has been associated with the development of T2DM and CV disease. Objective: We investigated the effects of the intake of a sweetened beverage, obtained from natural carbohydrates containing pinitol (PEB) compared to a sucrose-enriched beverage (SEB) in the context of impaired glucose tolerance (IGT) and diabetes. Methods: The study was divided in three different phases: (1) a discovery phase where the plasma proteomic profile was investigated by 2-DE (two-dimensional electrophoresis) follow…

Blood GlucoseMaleProteomicstype 2 diabetes mellitusmedicine.medical_treatmentType 2 diabetes030204 cardiovascular system & hematologyBody Mass IndexImpaired glucose tolerance0302 clinical medicineInsulinInsulin-Like Growth Factor INutrition and DieteticsbiologyChemistryComplement C4aFabaceaeMiddle AgedHealthy Volunteerslcsh:Nutrition. Foods and food supplyNutritive SweetenersAdultmedicine.medical_specialtyAdolescentsweetenerBlood sugarlcsh:TX341-641030209 endocrinology & metabolismCarbohydrate metabolismArticleDiabetes Mellitus ExperimentalBeveragesinsulin-like growth factor03 medical and health sciencesYoung AdultInsulin resistanceDouble-Blind MethodInternal medicineDiabetes mellitusGlucose IntolerancemedicineAnimalsHumansC4A complementAgedGlycated HemoglobinPlant ExtractsInsulinOverweightmedicine.diseaseRatsRats Zuckerimpaired glucose tolerance; type 2 diabetes mellitus; sweetener; insulin-like growth factor; C4A complementDisease Models AnimalEndocrinologyimpaired glucose toleranceDiabetes Mellitus Type 2biology.proteinGLUT2InositolFood ScienceNutrients; Volume 10; Issue 3; Pages: 271
researchProduct

POSTPRANDIAL HYPERGLYCEMIA IS A DETERMINANT OF PLATELET ACTIVATION IN EARLY 2 DIABETES MELLITUS

2010

BACKGROUND: Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus. OBJECTIVES: To evaluate the effects of acarbose, an alpha-glucosidase inhibitor, on platelet activation and its determinants in newly diagnosed type 2 diabetic patients. METHODS: Forty-eight subjects (26 males, aged 61 +/- 8 years) with early type 2 diabetes (baseline hemoglobin A(1c) < or = 7% and no previous hypoglycemic treatment) were randomly assigned to acarbose up to 100 mg three times a day or placebo, and evaluated every 4 weeks for 20 weeks. The main outcome measures were urinary 11-dehydro-thromboxane (TX)B(2) (marker of in vivo platelet activation) and 8-iso-prostaglandi…

Blood GlucoseMaleTime FactorsSettore MED/09 - Medicina InternaDinoprostpostprandial hyperglycemia; platelet activationMedicineEnzyme InhibitorsSettore MED/49 - Scienze Tecniche Dietetiche Applicatepostprandial hyperglycemiaAcarboseplateletHemoglobin AHematologyMiddle AgedPostprandial PeriodP-SelectinPostprandialTreatment OutcomeC-Reactive ProteinItalyFemaleBiological MarkersAcarboseType 2medicine.drugacarbose platelet activation postprandial hyperglycemia type 2 diabetes mellitusmedicine.medical_specialtySettore BIO/14 - FARMACOLOGIAUrinary systemCD40 LigandGlycosylatedArginineExcretionBlood Glucose; Time Factors; Lipid Peroxidation; Middle Aged; Hemoglobin A Glycosylated; Postprandial Period; Diabetes Mellitus Type 2; Enzyme Inhibitors; Hypoglycemic Agents; P-Selectin; Platelet Activation; Aged; CD40 Ligand; Treatment Outcome; Male; Female; Thromboxane B2; Dinoprost; Italy; Arginine; Acarbose; Double-Blind Method; Humans; Biological Markers; Hyperglycemia; alpha-Glucosidases; C-Reactive ProteinDouble-Blind MethodInternal medicineDiabetes mellitusDiabetes MellitusHypoglycemic AgentsHumansGlycoside Hydrolase InhibitorsPlatelet activationGlycemicAgedGlycated Hemoglobinbusiness.industryType 2 Diabetes Mellitusalpha-Glucosidasesmedicine.diseasePlatelet ActivationThromboxane B2EndocrinologyDiabetes Mellitus Type 2HyperglycemiaLipid PeroxidationbusinessBiomarkers
researchProduct

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

2014

Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. Methods In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week, active-controlled extension in which placebo-treated patients were switched to sitagliptin 100 mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52 (sitagliptin used to maintain double-blind and control for safety). Safety data ar…

Blood GlucoseMaleendocrine system diseasesEndocrinology Diabetes and Metabolismphase 3 studyBlood PressureType 2 diabetesPharmacologyEndocrinologyGlucosidesWeight lossCanagliflozinCandidiasisSGLT2 inhibitorMiddle AgedDiuretics OsmoticLipidsMetforminMetforminTreatment OutcomePyrazinesDrug Therapy CombinationFemaletype 2 diabetesmedicine.symptomSGLT2 InhibitorGenital Diseases Malemedicine.drugmedicine.medical_specialtyUrologyThiophenesDouble-Blind MethodWeight LossInternal MedicinemedicineHumansHypoglycemic AgentsCanagliflozinthiazolidinedionesPioglitazonebusiness.industrySitagliptin Phosphatenutritional and metabolic diseasesType 2 Diabetes MellitusOriginal ArticlesTriazolesmedicine.diseaseBlood pressureDiabetes Mellitus Type 2businessPioglitazoneGenital Diseases FemaleDiabetes, obesitymetabolism
researchProduct

Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience.

2017

Introduction. This study aimed at evaluating the efficacy and safety of dapagliflozin in patients with type 2 diabetes (T2D) who also received metformin in clinical practice in Italy. Methods. This was a retrospective observational study and it included data from patients who received dapagliflozin 10 mg once daily in conjunction with metformin for 12 months (DAPA + MET). In those with inadequate glycemic control, insulin or glimepiride was added after 30 days (DAPA + MET + other glucose-lowering drugs). Efficacy assessments included glycosylated hemoglobin (HbA1c) levels at 6 and 12 months, as well as body mass index (BMI) and lipid parameters at 12 months. Safety was also assessed. Result…

Blood GlucoseMalemedicine.medical_specialtyArticle Subjectendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabeteslcsh:Diseases of the endocrine glands. Clinical endocrinologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agents030212 general & internal medicineDapagliflozinBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinlcsh:RC648-665business.industryType 2 Diabetes Mellitusnutritional and metabolic diseasesRetrospective cohort studyMiddle Agedmedicine.diseaseMetforminMetforminTreatment OutcomechemistryDiabetes Mellitus Type 2Observational studyDrug Therapy CombinationFemalebusinessBody mass indexmedicine.drugResearch ArticleJournal of diabetes research
researchProduct